Widespread distribution of nirsevimab to infants with respiratory syncytial virus infection raised concerns about potential ...

Overall, 44.6 percent of 866 women with an infant born during August 2023 to March 2024 reported infant receipt of nirsevimab ...

The good news: In October, a new preventive medicine, the monoclonal antibody Nirsevimab, became available to babies and at-risk toddlers to help protect them from RSV (Respiratory Syncytial Virus).

Thanks to research advances, two new effective prevention methods are now available. The first is nirsevimab, which is approved and recommended for infants 0–8 months old and select older ...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.

Nirsevimab has been hailed by Sanofi chief executive Paul Hudson as one of the brightest prospects in the company's pipeline, providing a brand new way to tackle RSV, which according to the World ...

The following is a summary of "Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children," published in the September 2024 issue of Pediatrics by Domachowske et al. Children who are ...

A large study has now begun to find out whether nirsevimab should be offered to all babies in the UK. Respiratory syncytial virus (RSV) is one of the main reasons children under five end up in ...

just southeast of Hamilton, where the monoclonal antibody nirsevimab will be provided to eligible infants. This season will be the first time in Ontario that nirsevimab (sold under the brand name ...

The study involving 8,000 babies in Europe showed the drug nirsevimab lowered RSV-related hospitalisations by 83%, drug firm Sanofi said. University Hospital Southampton (UHS), which took part in ...

Provider recommendation for maternal vaccination or infant nirsevimab linked to higher immunization coverage. HealthDay News — In the 2023 to 2024 respiratory syncytial virus (RSV) season ...